Systematic Review: ClearCode 34 – A Validated Prognostic Signature in Clear Cell Renal Cell Carcinoma (ccRCC)
Author:
Affiliation:
1. Department of Medical Oncology, Fox Chase Cancer Center, Philadelphia, PA, USA
2. Department of Medicine, Division of Hematology and Oncology, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA
Publisher
IOS Press
Subject
General Medicine
Reference24 articles.
1. Adjuvant sunitinib in high-risk renal-cell carcinoma after nephrectomy;Ravaud;N Engl J Med,2016
2. Adjuvant sunitinib or sorafenib for high-risk, non-metastatic renal-cell carcinoma (ECOG-ACRIN E2805): A double-blind, placebo-controlled, randomised, phase 3 trial;Haas;Lancet,2016
3. Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial;Sternberg;J Clin Oncol,2010
4. Harshman L . A phase III randomized study comparing perioperative nivolumab vs. observation in patients with localized renal cell carcinoma undergoing nephrectomy (PROSPER RCC). Journal of Clinical Oncology 35(15_suppl).
5. Motzer RJ , et al. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results. Eur Urol. 2017.
Cited by 26 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献
1. Development and evaluation of a disulfidoptosis-related lncRNA index for prognostication in clear cell renal cell carcinoma;Heliyon;2024-06
2. Identifying genes associated with disease outcomes using joint sparse canonical correlation analysis—An application in renal clear cell carcinoma;Genetic Epidemiology;2024-05-15
3. Identification of novel snoRNA-based biomarkers for clear cell renal cell carcinoma from urine-derived extracellular vesicles;Biology Direct;2024-05-13
4. Management of Renal Cell Carcinoma: Promising Biomarkers and the Challenges to Reach the Clinic;Clinical Cancer Research;2023-11-09
5. The chromosomal instability 25 gene signature is identified in clear cell renal cell carcinoma and serves as a predictor for survival and Sunitinib response;Frontiers in Oncology;2023-05-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3